FDA Aims To Rebuild Its Science Reputation, Plans New Projects
This article was originally published in The Pink Sheet Daily
Executive SummarySeven priority areas include rapid detection of contaminants, adverse event detection and analysis, biomarkers, and clinical trial design and analysis.
You may also be interested in...
In a report on best practices for guidance development, FDA encourages outside groups to submit their own draft guidance proposals to help make the overall process more efficient.